Ascentage Pharma Group International Stock Price, News & Analysis

Ascentage Pharma (NASDAQ: AAPG) said its management will participate in three investor conferences in October 2025.

Events and dates: Piper Sandler Virtual Oncology Symposium — fireside chat at 10:30 AM EDT on October 10, 2025; J.P. Morgan Global Healthcare Shanghai Conference — one-on-one and group investor meetings on October 16–17, 2025; BofA China Trailblazers Biotech Conference — one-on-one investor meetings on October 20–21, 2025.

Ascentage Pharma (NASDAQ: AAPG), a global commercial-stage biopharmaceutical company, has announced its participation in three major investor conferences in September 2025. The company will present at Citi's 2025 Biopharma Back to School (September 3), the Cantor Global Healthcare Conference 2025 (September 4), and the H.C. Wainwright 27th Annual Global Investment Conference (September 10).

Live webcasts for the Citi and Cantor events will be available on the company's investor relations website, with replays accessible for 30 days after the events.

Ascentage Pharma (NASDAQ: AAPG) reported strong H1 2025 financial results, with Olverembatinib sales surging 93% year-over-year to $30.3 million. The company achieved a significant milestone with the approval of Lisaftoclax, the first Bcl-2 inhibitor for CLL/SLL treatment in China.

Total revenue was $32.6 million, down 71.6% year-over-year due to prior year's one-time IP revenue. The company reported a net loss of $82.5 million ($0.24 per share). Cash position strengthened to $231.9 million, further bolstered by a $190.1 million top-up placement in July 2025.

Nine registrational trials are actively progressing, including three FDA-cleared studies. The company expanded its commercial reach with Olverembatinib now available in 782 DTP pharmacies and hospitals, representing a 17% increase year-over-year.

Ascentage Pharma (NASDAQ: AAPG) has received clearance from both the FDA and EMA to conduct the GLORA-4 study, a global Phase III registrational trial for lisaftoclax in combination with azacitidine. The study targets first-line treatment of higher-risk myelodysplastic syndrome (HR-MDS).

Lisaftoclax, a proprietary Bcl-2 inhibitor, is currently the only Bcl-2 inhibitor in Phase III trials for HR-MDS globally. Earlier studies showed promising results with a 75% overall response rate, significantly higher than current standard treatments. The multi-region, multi-center, randomized, double-blind trial is simultaneously enrolling patients in China, the U.S., and Europe.

If successful, lisaftoclax could become the first targeted therapy approved for HR-MDS first-line treatment since the introduction of hypomethylating agents, potentially addressing a significant unmet medical need in this field.

Ascentage Pharma (NASDAQ: AAPG), a global biopharmaceutical company focused on cancer treatments, will release its 2025 six-month interim results on August 20, 2025, at 7:00 PM EDT.

The company will host two investor webcasts with Q&A sessions: a Chinese language presentation on August 20 at 9:00 PM EDT, and an English language presentation on August 21 at 8:00 AM EDT. Both events will feature the company's management team and require advance registration.

Ascentage Pharma (NASDAQ: AAPG), a global biopharmaceutical company focused on cancer treatments, has announced its participation in the upcoming Evercore China Biotech Summit scheduled for August 19-21, 2025 in Shanghai, China.

The company's management will engage in a fireside chat with the Evercore ISI Research team and conduct one-on-one meetings with investors during the conference. Interested investors can arrange meetings through their Evercore representatives.

Ascentage Pharma (NASDAQ: AAPG), a global biopharmaceutical company focused on cancer treatments, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.

The company's management team will be available for one-on-one meetings with investors throughout the conference. Interested investors should contact their BTIG representative to schedule meetings.

Ascentage Pharma (NASDAQ: AAPG) has successfully completed an offshore placement of 22 million ordinary shares at HKD68.60 per share. The placement was conducted by Dajun Yang Dynasty Trust, affiliated with the company's CEO. In a related transaction, the company will issue the same number of replacement shares to the trust, generating net proceeds of approximately HKD1,492 million (US$190.1 million).

The newly issued shares represent 6.29% of the company's pre-placement share capital. The proceeds will fund commercialization efforts, global clinical development of core pipeline candidates, and strengthen global operations. The transaction, managed by J.P. Morgan and Citigroup, was conducted outside the U.S. to non-U.S. persons under Regulation S.

Ascentage Pharma (NASDAQ: AAPG) has announced the pricing of a significant share placement involving 22 million ordinary shares at HKD68.60 per share. The placement, conducted by CEO Dajun Yang's affiliated trust, will generate gross proceeds of approximately HKD1,509.2 million (US$192.3 million).

The highly successful offshore placement was oversubscribed by eight times and is expected to close on July 17, 2025. Following the placement, the CEO's trust will subscribe to an equal number of new shares at the same price. The company plans to use the proceeds for commercialization efforts, global clinical development of core pipeline candidates, and strengthening global operations.